ACS Medicinal Chemistry Letters · 2019 · 28 citations · 9 references
Antifibrotic TherapyGood Kinome SelectivityNovel TherapyMedicineReceptor Tyrosine KinaseImmunologyReceptor (Biochemistry)Therapeutic EfficacyCollagen-iv ProductionPharmacotherapyCollagen-induced Ddr1 ActivationAnti-cancer AgentPharmacologyTumor MicroenvironmentDrug Discovery
Herein, we report the discovery of a potent and selective dual DDR1/2 inhibitor, 7e (VU6015929), displaying low cytotoxicity, good kinome selectivity, and possessing an acceptable in vitro DMPK profile with good rodent in vivo pharmacokinetics. VU6015929 potently blocks collagen-induced DDR1 activation and collagen-IV production, suggesting DDR1 inhibition as an exciting target for antifibrotic therapy.
9